BioXcel Therapeutics Inc. 于2026年美国临床精神药理学会（ASCP）年会上，公布了其SERENITY At-Home 3期临床试验的新数据。该试验旨在评估其疗法对与双相情感障碍或精神分裂症相关的急性激越的疗效与安全性。
此次公布的数据进一步揭示了该居家给药方案在控制患者激越症状方面的潜力。结果显示，治疗达到了预设的主要疗效终点，与安慰剂相比，在关键评估时间点上表现出具有统计学显著性的症状改善。同时，安全性数据与已知的安全性特征一致。
这些新发现为BioXcel Therapeutics的核心产品线提供了重要支持，特别是在满足精神健康领域对有效且便捷的急性干预措施的迫切需求方面。公司表示，这些数据将有助于推进该疗法的后续监管沟通与开发计划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.